cs.DBNov 9, 2026

LUCQUE: A lung cancer screening dataset from Québec for reliable AI evaluation

Authors: Johanna Topalis, Yannick Lemaréchal, Gabriel Couture, Hanife Ersay, Loran Nas, Balthasar Schachtner, Bastian Oliver Sabel, Michael Ingrisch, 

Organizations: Department of Radiology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany · relAI – Konrad Zuse School of Excellence in Reliable AI, Munich, Germany · Munich Center for Machine Learning (MCML), Munich, Germany · Comprehensive Pneumology Center (CPC-M), Member of the German Center for Lung Research (DZL), Munich, Germany · 

Abstract

BACKGROUND: AI-based tools are expected to play a key role in lung cancer screening (LCS). The evaluation of these tools often relied on private datasets or fragmented public datasets with inconsistent availability of clinical data and expert nodule annotations. This has hindered reproducibility, comparability, and independent assessment of AI tools. To address these gaps, we present LUCQUE, a novel, large, comprehensively annotated dataset derived from LDCT lung cancer screening in Québec, which is accessible for reliable AI evaluation. METHODS: LUCQUE was curated and is hosted on PARADIM, a digital infrastructure supporting DICOM data de-identification, annotation, long-term storage and analysis. LDCT scans and clinical information were combined to a curated collection and complemented by voxel-level, expert-derived pulmonary nodule and cyst segmentations, and Lung-RADS-based lesion characteristics. Key dataset characteristics and statistics were reported, including participant demographics, imaging parameters, radiological findings, and segmented lesion characteristics. Dataset analyses were conducted according to PARADIM's model-to-data approach, in which user code is executed on the platform such that data remains on premise. RESULTS: LUCQUE currently comprises 1,678 LDCT baseline studies from 1,678 participants. Most studies were classified as Lung-RADS 2. A total of 1,776 pulmonary nodules and 60 cysts were annotated, with a median (interquartile range) volume of 89 (56, 159) mm389\,(56,\,159)\,\mathrm{mm}^3 and 1,384 (589, 3793) mm31,384\,(589,\,3793)\,\mathrm{mm}^3 respectively. CONCLUSIONS: Compared to publicly available LCS datasets, LUCQUE currently represents the largest accessible annotated real-world LCS dataset. Access to LUCQUE is provided via a model-to-data approach, enabling privacy-preserving, reproducible, and independent real-world evaluation of AI tools in LCS.

Explore similar work

Aug 14, 2026

AMPLIFAI: A Multiphase CT Dataset for Benchmarking Clinical Reasoning in LI-RADS Assessment of Liver Lesions

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related mortality worldwide, with early detection improving survival from <20% to >70%. The standardized Liver Imaging Reporting and Data System (LI-RADS) criteria provide an imaging-based diagnostic framework to evaluate liver lesions for HCC, serving as a foundation for automating HCC detection with artificial intelligence (AI). However, the lack of large, publicly available datasets with high-quality annotations has limited the development and evaluation of AI models for automated LI-RADS assessment. We introduce AMPLIFAI dataset, the first public dataset of 590 multiphase abdominal CT studies annotated with LI-RADS categories, lesion size, and voxel-level segmentations for three major LI-RADS features: arterial phase hyperenhancement, washout, and enhancing capsule. The dataset was curated and harmonized from four public datasets and augmented with expert annotations from five board-certified radiologists and one resident. Following the Datasheets for Datasets format, this paper details the dataset's composition, curation and harmonization process, and annotation workflow to support transparent, reproducible research in medical imaging AI.
Oct 13, 2025

Benchmarking Deep Learning Models for Laryngeal Cancer Staging Using the LaryngealCT Dataset

Laryngeal cancer imaging research lacks standardised public datasets to enable reproducible deep learning (DL) model development. We present LaryngealCT, a curated benchmark of 1,029 computed tomography (CT) scans aggregated from six collections from The Cancer Imaging Archive (TCIA). Uniform 1 mm isotropic volumes of interest encompassing the larynx were extracted using a weakly supervised parameter search framework validated by clinical experts. Six 3D DL architectures (custom 3D CNN, ResNet18,50,101, DenseNet121 and MedicalNet-pretrained ResNet50) were benchmarked on (i) early (Tis,T1,T2) vs. advanced (T3,T4) and (ii) T4 vs. non-T4 classification tasks. On the independent test set, the 3D CNN achieved the strongest overall performance across global and per-class metrics (Accuracy 0.854, F1-macro 0.841) in early vs. advanced classification. In the T4 task, AU-ROC values exceeded 0.82 for most models, but sensitivity for T4 disease remained limited (less than or equal to 0.412), with ResNet101 showing the most promising calibrated T4 recall (0.706. Model explainability assessed using GradCAMpp with thyroid cartilage overlays for T4 classification task revealed anatomically plausible peri-cartilage activations, although spatial overlap was modest. Through open-source data, pretrained models, and integrated explainability tools, LaryngealCT offers a reproducible foundation for AI-driven research to support future clinical decision-making in laryngeal oncology.
Aug 24, 2026

LUCAID: Agentic Multimodal AI for Lung Cancer Precision Pathology

Lung cancer tissue diagnostics is complex, as therapy decisions in precision oncology rely on the integration of histomorphological, immunohistochemical, and molecular features. Yet pathological assessment remains largely visual and semi-quantitative and shows interobserver variability, while existing artificial intelligence (AI) tools cover only selected tasks, rarely reach generalizable expert-level performance, and lack prospective clinical validation. To address these challenges, we developed and clinically validated LUCAID, an agentic AI system for precision lung cancer pathology. An integrative agent couples diagnostic reasoning with nine modules that cover the full routine workflow, from quality control, tumor detection and segmentation, histological subtyping, tumor microenvironment profiling, tumor cellularity quantification, and predictive biomarker scoring (PD-L1, MET, TROP-2) to automated structured report generation. LUCAID enables users to interactively query the module outputs and generate reports that contextualize the results. Against large-scale expert ground-truth annotations, the analysis modules achieved F1 scores of 0.82-0.95. In prospective clinical validation, LUCAID reached 93.0% concordance with an expert-panel adjudicated reference standard across clinically actionable decisions, compared with 68.3-81.1% for five experienced thoracic pathologists.